Myopia in children isn't just a glasses problem — it's a growing public health concern. The rate of myopia in the U.S. has jumped from 25% in 1980 to 42% today, driven largely by increased screen time and near-vision demands. Left unchecked, progressive myopia raises lifetime risks of glaucoma, cataracts, retinal detachment, and myopic maculopathy — even at low levels.

The encouraging news is that pediatric progressive myopia (PPM) is now treatable, and the options are expanding. Eye care providers are urged to identify at-risk children early — even a 5-year-old who is emmetropic (rather than slightly farsighted) may already be on a concerning trajectory, especially with a family history of myopia.

Key Takeaways:

• Behavioral changes like 2+ hours of daily outdoor activity, limiting near work, and the 20-20-20 rule are first-line, low-cost interventions
• Specialty eyeglasses (e.g., EssilorLuxottica Stellest) reduced myopia progression by 71% and axial elongation by 53% vs. standard lenses in a 2-year U.S. study
• MiSight contact lenses cut myopia progression by 59% and axial elongation by 52% in a 3-year multinational study
• Low-dose atropine drops (0.01%–0.05%) show strong supporting data; an FDA-approved version is pending, but compounded options are available for ~$50/month

Why it matters: Catching and treating PPM early can dramatically reduce a child's risk of serious eye disease later in life. For clinicians, staying current on the expanding treatment landscape is essential to delivering timely, effective care for young patients.